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Introduction
Meningioma is the most common primary 
intracranial tumors in adults, accounts for 36% of 
total intracranial tumors in the USA, with an incidence 
about 7.61/100,000 population [1]. The high recurrence 
of meningiomas remains a hurdle in clinical settings. 
The recurrence rate is not only determined by surgical 
grading but also histopathological grading. About 
7–32% benign meningiomas will relapse after total 
resection [2]. Prior study indicated that classical WHO 
grading failed to predict meningioma prognosis [3]. 
Lack of literatures regarding clinicopathological 
characteristics of meningioma in Indonesia adds more 
challenges for decision-making in the clinics.
Transforming growth factor-β (TGF-β) 
induces a pleiotropic pathway that is modulated by the 
cellular context and its integration with other signaling 
pathways. In cancer, TGF-β induces cytostatic and 
apoptotic responses in early-stage tumors, while 
inducing proliferation, invasion, angiogenesis, and 
immune evasion in advanced cancer [4]. Several 
conflicting evidences about TGF-β role in meningioma 
progression, initial study reported that TGF-β addition 
promotes meningioma cell proliferation [5], while later 
studies reported that dysregulation or loss of TGF-β 
signaling contributes to meningioma progression or 
meningioma agenesis [6],[7].
E-cadherin is a crucial molecule in intercellular 
adhesion in epithelial tissues. It is localized on the 
surfaces of epithelial cells in regions of cell-cell contact 
known as an adherent junction [8]. Besides its role in 
physiological condition, this highly conserved gene 
contributes to malignant transformation, especially 
in tumor development and progression. The loss of 
E-cadherin is regarded as a major molecular event 
for dysfunction in cell-cell adhesion, particularly 
during epithelial–mesenchymal transition (EMT) [9]. 
Most tumors have abnormal cellular architecture and 
loss of tissue integrity, thus lead to local invasion and 
metastasis [10]. Prior studies in meningiomas hinted 
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Abstract
BACKGROUND: Meningioma is the most common primary intracranial tumors in adults, accounts for 36% of total 
intracranial tumors. Obtaining the clinicopathological characteristics of patients with meningioma and investigating, 
the association between signaling pathways with disease progression could provide a basis for therapeutic 
development.
AIM: This study aims to investigate the expression of transforming growth factor-β1 (TGF-β1), E-cadherin, and Ki-67 
in meningiomas.
MATERIALS AND METHODS: This study examined the expression levels of E-cadherin, Ki-67, and TGF-β1 with 
respect to the WHO grade in patients with meningioma. A total of 62 meningioma samples were analyzed. By the 
WHO criteria, 54 specimens were diagnosed as the WHO Grade 1, 6 as Grade 2, and 2 as Grade 3. Grade 1 was 
classified as low-grade meningioma, while Grade 2 and Grade 3 were classified as high-grade meningioma (HGM).
RESULTS: In this study, the mean age diagnosis was 41.97 ± 9.79 years old, with female: male ratio of 8:1. There was 
no association between age, sex, and tumor location with the progression of meningioma. Immune-characterization 
revealed that HGM was associated with the higher number of Ki-67+ cells (p < 0.0001) and lower expression of 
TGF-β1 and E-cadherin (p < 0.001). The number of Ki-67+ cells was inversely correlated with TGF-β1 and E-cadherin 
(p < 0.05). TGF-β1 expression was positively correlated with E-cadherin expression (p < 0.0001).
CONCLUSION: This study concluded that HGM was highly proliferative (high Ki-67+) and invasive (low E-cadherin), 
with dysregulated TGF-β1 signaling. In addition, younger age at diagnosis and high female: male ratio in our series 
suggests that Indonesian females might possess specific risk factors for having meningioma.
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that E-cadherin was dysregulated in meningioma and 
might contribute to meningioma agenesis [11],[12].
The association between TGF-β1 and 
E-cadherin has been reported in several tumors. In 
gastric cancer, TGF-β1 overexpression contributes to 
decreased expression of E-cadherin; this phenomenon 
involves in the progression of gastric cancer [13]. A similar 
association was observed in colorectal cancer, TGF-β1 
expression is inversely correlated with E-cadherin 
expression [14]. In this study, we aim to investigate 
TGF-β1 and E-cadherin expression in meningioma, to 
clarify the association between TGF-β1, E-cadherin, 
and Ki-67, and to gain better insight regarding those 
signaling in meningioma genesis. In addition, we also 
aim to obtain the clinicopathological characteristics of 
patients with meningioma in Indonesia and to provide a 
basis for therapeutic development.
Materials and Methods
Patients
This retrospective study included 62 patients 
at Raden Mattaher Hospital, Jambi, who underwent 
surgical resection from January 2012 to December 
2017, in which the diagnosis of meningioma was 
established. Clinical data were collected from archival 
medical records. Surgically resected tumor tissues 
were fixated in 10% – formaldehyde and preserved in 
paraffin-embedded blocks. Tumors were then classified 
and graded according to the 2016 WHO classification 
of CNS tumors [15]. Clinical data of patients are 
summarized in Table 1.
Immunohistochemistry (IHC)
Four-micron thickness slides from the tumor tissue 
were deparaffinized and rehydrated. Antigen retrieval 
was carried out with microwave and antigen retrieval 
solution (citrate buffer 10 mmol/L, pH 6.0). Sections 
were then allowed for cooling at room temperature, 
followed by washing 3×, each for 5 min with phosphate-
buffered saline (PBS). Endogenous peroxidase activity 
was blocked by dipping sections in 3% H2O2 (Dako, 
USA) for 3 min, then 0.3% H2O2 (Dako, USA) for 30 min, 
and washed in three changes of PBS. Then, slices 
were incubated with 0.3% Triton X-100 for membrane 
penetration. Non-specific protein binding was blocked 
with 2% normal goat serum (Millipore, USA) for 20 min 
at room temperature. Slices were incubated with 
primary antibodies overnight at 40°C. After washing 
in three changes of PBS, slices were incubated with 
biotinylated secondary antibodies for 30 min at room 
temperature. Slices were washed with PBS ×3, 
followed by incubation with horseradish peroxidase 
labeled avidin-biotin complex (Vectastain, PK-6100, 
Vector Laboratories) for 30 min. After washing, the 
staining was developed for 5 min in a substrate 
medium containing 0.05% 3,3-diaminobenzidine and 
0.02% H2O2 in Tris-HCl buffer (pH 7.6). The specificity 
of staining was confirmed by the absence of staining 
when the primary antibodies were omitted. The slices 
were counterstained with hematoxylin and mounted 
with Entellan (Millipore, USA).
Table 1: Summary of patients characteristics
No Sex Age Location Histological type WHO grade
1 Female 46 Cranial vault Meningotheliomatous 1
2 Male 66 Cranial vault Meningotheliomatous 1
3 Female 43 Cranial vault Meningotheliomatous 1
4 Female 31 Cranial vault Meningotheliomatous 1
5 Female 42 Cranial vault Psamommatous 1
6 Female 55 Cranial vault Meningotheliomatous 1
7 Female 42 Cranial vault Psamommatous 1
8 Female 39 Cranial vault Meningotheliomatous 1
9 Male 50 Skull base Meningotheliomatous 1
10 Female 43 Cranial vault Meningotheliomatous 1
11 Female 40 Cranial vault Meningotheliomatous 1
12 Female 28 Cranial vault Angiomatous 1
13 Female 38 Cranial vault Meningotheliomatous 1
14 Male 38 Cranial vault Angiomatous 1
15 Female 28 Skull base Meningotheliomatous 1
16 Female 43 Skull base Fibroblastic 1
17 Female 45 Cranial vault Psamommatous 1
18 Female 28 Skull base Meningotheliomatous 1
19 Female 56 Cranial vault Meningotheliomatous 1
20 Female 42 Skull base Meningotheliomatous 1
21 Female 34 Cranial vault Meningotheliomatous 1
22 Female 43 Skull base Meningotheliomatous 1
23 Male 35 Cranial vault Angiomatous 1
24 Female 32 Cranial vault Psamommatous 1
25 Female 47 Skull base Meningotheliomatous 1
26 Female 23 Cranial vault Fibroblastic 1
27 Male 33 Cranial vault Angiomatous 1
28 Female 48 Cranial vault Meningotheliomatous 1
29 Female 45 Cranial vault Meningotheliomatous 1
30 Female 36 Skull base Meningotheliomatous 1
31 Female 46 Skull base Meningotheliomatous 1
32 Female 68 Cranial vault Psamommatous 1
33 Male 41 Cranial vault Meningotheliomatous 1
34 Female 30 Cranial vault Meningotheliomatous 1
35 Female 24 Cranial vault Angiomatous 1
36 Female 43 Skull base Meningotheliomatous 1
37 Female 46 Cranial vault Meningotheliomatous 1
38 Female 60 Skull base Meningotheliomatous 1
39 Female 56 Cranial vault Angiomatous 1
40 Female 43 Cranial vault Meningotheliomatous 1
41 Female 38 Cranial vault Meningotheliomatous 1
42 Female 44 Cranial vault Angiomatous 1
43 Female 52 Skull base Meningotheliomatous 1
44 Female 35 Cranial vault Fibroblastic 1
45 Male 44 Skull base Angiomatous 1
46 Male 48 Cranial vault Meningotheliomatous 1
47 Female 26 Skull base Angiomatous 1
48 Female 39 Cranial vault Meningotheliomatous 1
49 Female 40 Cranial vault Psamommatous 1
50 Female 43 cranial vault Meningotheliomatous 1
51 Female 38 Skull base Angiomatous 1
52 Female 36 Skull base Fibroblastic 1
53 Female 30 Cranial vault Microcystic 1
54 Female 40 Cranial vault Psamommatous 1
55 Female 44 Cranial vault Atypical 2
56 Female 51 Skull base Chordoid 2
57 Female 51 Skull base Atypical 2
58 Female 66 Cranial vault Chordoid 2
59 Female 33 Cranial vault Atypical 2
60 Female 35 Skull base Atypical 2
61 Female 48 Cranial vault Anaplastic 3
62 Female 45 Cranial vault Anaplastic 3
IHC analysis
Slices were observed and images were 
captured with Olympus BX51 (Tokyo, Japan) by a 
blinded experimenter. The percentage of Ki-67+ 
cells was counted on five non-overlapping fields 
at ×40 objective magnification, at least 500 cells. Semi-
quantitative scoring was utilized to determine TGF-β1 
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and E-cadherin immunoreactivity. The average counts 
of the five regions were used for the final report.
Research ethics
Ethical approval was obtained from the Faculty 
of Medicine, Andalas University, and Dr. M. Djamil 
Hospital, Padang, Committee of Ethics.
Statistical analysis
Statistical analysis was performed using 
GraphPad Prism 7.03. The data were evaluated for 
normality distribution before statistical comparison. 
Fisher Exact test was used to examine the difference 
between female and cranial vault proportion between 
low-grade meningioma (LGM, WHO Grade I) and high-
grade meningioma (HGM, WHO Grade II-III). T-test 
was used to examine the difference of age at diagnosis 
between LGM and HGM. The Mann–Whitney U-test 
was used to examine the difference between LGM 
and HGM, in terms of Ki-67, E-cadherin, and TGF-β1 
expression. The association between each variable 
was evaluated by linear regression. The statistically 
different consider significant when p < 0.05.
Results
Patients characteristics
We enrolled 62 patients diagnosed with cranial 
meningiomas, which tumor specimens were available. 
By the WHO criteria [15], 54 of the specimens were 
diagnosed as Grade I, six as Grade II, and two 
as Grade III. In the case of Grade I meningioma, 
meningiotheliomatous was the most common type, 
about 59.26% (32/54), followed by angiomatous 
(18.52%), psamommatous (12.96%), fibroblastic 
(7.41%), and microcystic (1.85%). In the case of 
Grade II, atypical was the most common type, about 
66.67% (4/6), the other type was chordoid (33.33%). 
All Grade III meningiomas were anaplastic variants 
(2/2). To ease further analysis, we classified Grade I 
meningiomas as LGM and Grade II-III meningiomas as 
HGM.
There was no difference in the mean age at 
the diagnosis of meningioma between LGM and HGM 
(41.28 ± 9.61 vs. 46.63 ± 10.32, p = 0.1508). In this 
study, meningioma was rarely observed in the elderly 
population (>65 years old, 4.84% [3/62]). The female 
proportion was not statistically different between LGM 
and HGM (46/54 vs. 8/8, p = 0.5810). In this study, 
we observed a high female proportion (±8:1), which 
higher than literatures [2,16]. There was no difference 
in cranial vault meningioma proportion between LGM 
(70.37%, 38/54) and HGM (62.50%, 5/3, p = 0.6917). 
Patient characteristics are summarized in Table 1.
IHC results of meningioma patients
To gain insight about TGF-β1 and E-cadherin 
association in meningioma, we performed IHC to 
examine: Ki-67, TGF-β1, and E-cadherin. We observed 
that HGM tumor specimens were more proliferative 
than LGM (Ki-67+ cells: 11.38 ± 2.15% vs. 3.83 ± 
1.05%, p < 0.0001, Mann–Whitney U-test, Figures 1a, 
d, g and 2a).
Figure 1: Representative immunostaining on meningioma tissues. 
Ki-67 was nuclear staining (left panel). E-cadherin (middle panel) was 
cytoplasmic staining. TGF-β1 was cytoplasmic and extracellular matrix 
staining (right panel). Low Ki-67+ meningiomas were associated with 
high expression of E-cadherin and TGF-β1 (upper panel). Moderate 
Ki-67+ meningiomas were associated with moderate expression of 
E-Cadherin and TGF-β1 (middle panel). High Ki-67+ meningiomas 
were associated with low expression of E-cadherin and TGF-β1 
(lower panel). Scale Bar = 100 μm. TGF-β1: Transforming growth 
factor-β1
In this study, we observed that E-cadherin 
expression was lower in HGM than LGM (7.32 ± 2.17 
vs. 4.25 ± 1.17, p < 0.0001, Mann–Whitney U-test, 
Figures 1b, e, h and 2b). TGF-β1 expression was also 
observed to be lower in HGM than LGM (6.39 ± 2.03 
vs. 3.75 ± 1.58, p = 0.0002, Mann–Whitney U-test, 
Figures 1c, f, i and 2c). Further analysis revealed that 
the number of Ki-67+ cells was inversely correlated with 
E-cadherin and TGF-β1 expression (Figure 2d and e). 
We also confirmed that E-cadherin expression was 
associated with TGF-β1 expression (Figure 2f).
Discussion
In this series, the majority of meningiomas were 
LGM (87.10%, 54/62), this finding is consistent with 
reported literatures, LGM accounts for 70–90% of total 
meningiomas [17],[18] suggesting that the proportion of 
aggressive meningiomas (HGM) in Indonesia is similar 
with other countries. The majority of meningiomas 
a b c
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were located in the cranial vault (convexity, falx, and 
parasagittal), accounts for 69.35% (43/62) of total 
patients; this finding resembles the reported proportion 
in India [19]. Additionally, during 2012–2018, in 
Dr Hasan Sadikin Hospital (Tertiary Neurosurgery 
Center, Bandung, Indonesia), cranial vault meningioma 
only accounts for ±25% from a total of 717 meningiomas 
(Hermanto and Faried, unpublished data). This 
discrepancy might be attributed to genetic background 
as well as the tendency for referring difficult cases (skull 
base meningioma) to the tertiary care hospital.
In this series, meningiomas were commonly 
observed in middle-aged (30–55 years old) population 
with a female predominance (8:1); meanwhile, the 
reported incidence of meningioma is higher in elderly, with 
the female:male ratio of 3.5:1 [2],[19],[20]. The previous 
study indicated that male and convexity meningiomas 
are the risk factors for having HGM [2],[21]; however, 
we did not those associations in our series. Together, 
our findings suggest that Indonesian females possess 
specific risk factors that might increase the likelihood of 
having meningioma.
We observed a unique association between 
WHO Grade, Ki-67, E-cadherin, and TGF-β1, suggesting 
HGM was highly proliferative (high Ki-67+) and invasive 
(low E-cadherin), with dysregulated TGF-β1 signaling. 
The role of TGF-β signaling in cancer is intriguing, 
exhibiting context-dependent effects. It may act as a tumor 
suppressing factor or tumor promoting factor. In normal 
cells and early-stage cancers, TGF-β inhibits cell growth 
and promotes apoptosis [22]. However, its activation in 
late-stage cancers promotes cell growth, immune evasion, 
angiogenesis, chemoresistance, and invasion [22]. 
Several reports indicated that the upregulation of TGF-β 
in cancers promotes downregulation of E-cadherin and 
contributes to the EMT [13],[14],[23]. Interestingly, we 
found that TGF-β1 is downregulated in HGM, although 
HGM is more proliferative and invasive. Previous studies 
demonstrated that TGF-β addition inhibits meningioma 
cell proliferation [6],[24]. Gene expression profile also 
indicated that there is a loss of TGF-β signaling in 
HGM [7]. Hence, it seems likely that TGF-β exerts an 
inhibitory effect on LGM and that loss of TGF-β signaling 
results in progression to malignancy.
This study is limited by a small number of HGM, 
the malignant tumor itself is known for its intra- and inter-
tumoral heterogeneity. Of note, several reports indicated 
that activation of TGF-β signaling promotes proliferation 
and meningioma cells [5],[25], therefore further in vitro 
and in vivo investigations are needed to clarify the 
context-dependent of TGF-β signaling in meningioma. 
Younger age at diagnosis and high female: male ratio 
in our series suggests that Indonesian females might 
possess specific risk factors for having meningioma; it 
also needs for further investigation.
In this study, we found that HGM was highly 
proliferative (high Ki-67+) and invasive (low E-cadherin), 
with dysregulated TGF-β1 signaling. TGF-β1 is 
downregulated in HGM; hence, it seems likely that 
TGF-β exerts an inhibitory effect on LGM and that loss of 
TGF-β signaling results in progression to malignancy. In 
addition, younger age at diagnosis and high female: male 
ratio in our series suggest that Indonesian females might 
possess specific risk factors for having meningioma.
Figure 2: Semi-quantitative analysis of immunostaining. (a) Ki-67 expression was observed to be higher in HGM (WHO Grade 2–3) (3.83 ± 
1.05 vs. 11.83 ± 2.15, p < 0.0001, Mann–Whitney U-test). (b) E-cadherin expression was lower in HGM than LGM (7.32 ± 2.17 vs. 4.25 ± 1.17, 
p < 0.0001, Mann–Whitney U-test). (c) TGF-β1 expression was lower in HGM than LGM (6.39 ± 2.03 vs. 3.75 ± 1.58, p = 0.0002, Mann–Whitney 
U-test). (d) E-cadherin expression was inversely correlated with Ki-67 expression. (e) TGF-β1 expression was inversely correlated with Ki-67 
expression. (f) E-cadherin expression was associated with TGF-β1 expression. HGM: High-grade meningioma. LGM: Low-grade meningioma
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